Agenus Inc

Wright Timothy’s purchase of 2,448 deferred units shows insider confidence in Agenus’s oncology pipeline—boosting board alignment, hinting at future share dilution, and signaling long‑term upside.

Armen Garo’s steady insider buying signals confidence in Agenus’s immuno‑oncology future, hinting at potential upside amid market volatility.

Insider buying surge at Agenus Inc. shows CEO Armen Garo purchasing 4,829 shares, signaling confidence in the biotech’s immuno‑oncology pipeline and potential upside amid market buzz.

Explore how Agenus insider moves and a $141 M partnership with Zydus signal potential upside amid a volatile stock and low P/E.